Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth Warning Letter Reflects Continued Difficulties With Hormone Manufacturing

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA cites the company for GMP violations involving the oral contraceptive Triphasil-28 and Prempro, which has had a slew of recalls in recent years.

You may also be interested in...



FDA Completes Wyeth Guayama Inspection But Has Remaining Concerns

Wyeth will provide update on the status of products under review at the agency on April 19.

FDA Completes Wyeth Guayama Inspection But Has Remaining Concerns

Wyeth will provide update on the status of products under review at the agency on April 19.

Wyeth Anticipates “Approvable” Letter For Effexor XR Follow-On

CEO Essner says issues at firm’s Puerto Rico manufacturing facility are one reason to expect an approvable letter.

Related Content

Topics

UsernamePublicRestriction

Register

PS064251

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel